Press Releases


DateTitle 
2/25/20
Live Audio Webcast will be on March 3, 2020 SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 40 th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday, Mar. 3, 2020 , in Boston .
2/4/20
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA® (valbenazine) Full-Year 2019 Net Product Sales of $753 Million with Approximately 132,700 TRx SAN DIEGO , Feb. 4, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc.
2/3/20
SAN DIEGO , Feb. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx, a clinical-stage biopharmaceutical company focused on
1/20/20
Conference Call and Webcast Scheduled for Tuesday, February 4 SAN DIEGO , Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020 .
1/12/20
- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx - INGREZZA® (valbenazine) Preliminary Full-Year 2019 Net Product Sales of Approximately $753 Million with Approximately 132,700 TRx SAN DIEGO , Jan.
1/10/20
Neurocrine Biosciences Owns Option to Exclusively License ACT-709478, a Clinical Stage Selective T-type Calcium Channel Blocker for the Treatment of Epilepsy Idorsia to Receive $45 Million Upfront Upon Exercise of the Option and up to $365 Million in Potential Development and Regulatory Milestone
1/6/20
SAN DIEGO , Jan. 6, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38 th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time ( 2:30 p.m. Eastern Time ) on Monday, Jan. 13, 2020 , in San Francisco .